Bluebird Bio upgraded to Buy from Neutral at BofA

BofA analyst blue‘>Jason Gerberry upgraded Bluebird Bio to Buy from Neutral with a price target of $10, up from $6. The firm argues that Bluebird’s sickle cell disease, or SCD, gene therapy product is “under-appreciated” and adds that it expects lovo-cel to “gain timely approval” by its December PDUFA deadline date. With lovo on the market for SCD, BofA forecasts Bluebird reaching profitability in 2026 and views the lovo-cel launch as a “prove it” event and catalyst for the shares, the analyst tells investors.